Forum Cookies Strain Guide Examines the History of the GSC Forum Cut and Historical Lab Data

Official Cannabis, a subsidiary of Real Tested Inc., published a Forum Cookies guide compiling lineage records and 81 historical flower tests reported under that name. The tests showed median total THC of 18.75%, versus 19.72% across 567 tests under the broader Girl Scout Cookies name; the guide cautions that these historical, name-matched results do not establish shared genetics or predict current products.

Analysis

This is a low-signal data/content announcement, not evidence of a change in cannabis product economics. The commercial angle is indirect: strain-specific reference content may improve search traffic, consumer discovery, or lead generation for Official Cannabis/Real Tested, but the release provides no audience, conversion, or revenue data to underwrite that opportunity.

The more durable industry implication is that strain names are weak proxies for genetic identity and product consistency. If retailers, platforms, or regulators increasingly demand traceable genetics and batch-level testing, operators with credible provenance and quality-control systems could gain differentiation; brands relying on familiar strain labels alone may find those labels less defensible. That remains a conditional, longer-term thesis—not a catalyst from this release. Historical, name-matched lab records do not establish current product potency or genetic equivalence, so the comparison should not be used to infer competitive product quality.

Near term, there is no apparent earnings, regulatory, or supply catalyst, and no mapped public issuer to trade. Over 6–18 months, monitor whether strain-reference publishers demonstrate monetizable traffic and whether retailers or regulators adopt stronger provenance standards. The thesis weakens if consumer discovery remains driven by price and retailer placement, or if provenance data fails to change purchasing behavior.

Key Decisions for Investors

• No trade on this announcement; it does not establish a material financial impact for a public company.
• Treat Real Tested’s potential as a watch item, not an investment thesis. Verify traffic, repeat usage, commercial partnerships, and conversion or licensing revenue before assigning value to its reference-guide strategy.
• For cannabis-sector exposure, monitor retailer and operator disclosures for spending or standards tied to genetic provenance, batch-level testing, and product consistency; those would be stronger indicators than historical strain-name datasets.
• Falsification/watch point: if provenance features fail to influence retailer placement, consumer choice, or regulatory requirements over the next 6–18 months, the proposed differentiation benefit is unlikely to accrue.